The protection and therapy effects of bortezomib in murine acute graft-versus-host disease

Transplantation Proceedings

Volumn 45, Issue 6, 2013, Pages 2527-2535

  Li, Z ^a   Wu, Q ^a   Yan, Z ^a   Li, D ^a   Lu, G ^a   Mou, W ^a   Wu, S ^a   Pan, X ^a   Lu, Q ^a   Xu, K ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DRUG EFFECT; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; TH17 CELL; THERAPY EFFECT;

ACUTE DISEASE; ANIMALS; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; BORONIC ACIDS; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRAZINES; TH17 CELLS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84882267768     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.03.042     Document Type: Article

References (29)

1. M. Li, K. Sun, L.A. Welniak, and W.J. Murphy Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease Expert Opin Pharmacother 9 2008 2305
2. A. Bacigalupo Management of acute graft-versus-host disease Br J Haematol 137 2007 87
3. A. Bacigalupo Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects Bone Marrow Transplant 35 2005 225
4. D. Blaise, D. Olive, and M. Michallet Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft versus-host prophylaxis Lancet 345 1995 1144
5. G.R. Hill, and J.L. Ferrara The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation Blood 95 2000 2754
6. P. Reddy, T. Teshima, and M. Kukuruga Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis J Exp Med 194 2001 1433
7. L.A. Welniak, B.R. Blazar, and R.H. Wiltrout Role of interleukin-12 in acute graft-versus-host disease Transplant Proc 33 2001 1752
8. R. Korngold, and J.C. Marini Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses Biol Blood Marrow Transplant 9 2003 292
9. Y. Yamamoto, and R.B. Gaynor IkappaB kinases: key regulators of the NF-kappaB pathway Trends Biochem Sci 29 2004 72
10. Q. Li, and I.M. Verma NF-kappaB regulation in the immune system Nat Rev Immunol 2 2002 725
11. T. Hideshima, P. Richardson, and D. Chauhan The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 2001 3071
12. W.H. McBride, K.S. Iwamoto, and R. Syljuasen The role of the ubiquitin/proteasome system in cellular responses to radiation Oncogene 22 2003 5755
13. N. Mitsiades, C.S. Mitsiades, and P.G. Richardson The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agent therapeutic applications Blood 101 2003 2377
14. T.R. Johnson, K. Stone, and M. Nikrad The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells Oncogene 22 2003 4953
15. T.J. Sayers, A.D. Brooks, and C.Y. Koh The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP Blood 102 2003 303
16. J.A. Fleming, E.S. Lightcap, and S. Sadis Complementary whole-genomic technologies reveal the cellular response to proteasome inhibition by PS-341 Proc Natl Acad Sci USA 99 2002 1461
17. S. Vodanovic-Jankovic, P. Hari, and P. Jacobs NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145 Blood 107 2006 827
18. K. Sun, L.A. Welniak, and A. Panoskaltsis-Mortari Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib Proc Natl Acad Sci U S A 101 2004 8120
19. K. Sun, D.E. Wilkins, and M.R. Anver Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity Blood 106 2005 3293
20. S.M. McDonough, B. Bindra, and P. Armand Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation J Clin Oncol 30 2012 3202
21. K.R. Cooke, L. Kobzik, and T.R. Martin An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: the roles of minor H antigens and endotoxin Blood 88 1996 3230
22. A. Panoskaltsis-Mortari, A. Price, and J.R. Hermanson In vivo imaging of graft versus host disease Blood 103 2004 3590
23. M. Sykes, M.L. Romick, and K.A. Hoyles In vivo administration of interleukin-2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment J Exp Med 171 1990 645
24. M. Sykes, G.L. Szot, and P.L. Nguyen Interleukin-12 inhibits murine graft-versus-host disease Blood 86 1995 2429
25. M. Sykes, D.A. Pearson, and P.A. Taylor Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients Biol of Blood Marrow Transplant 5 1999 277
26. L.J. Egan, L. Eckmann, and F.R. Greten IκB-kinaseβ-dependent NF-κB activation provides radioprotection to the intestinal epithelium Proc Natl Acad Sci U S A 101 2004 2452
27. W. Krenger, G.R. Hill, and J.L.M. Ferrara Cytokine cascades in acute graft-versus-host disease Transplantation 64 1997 553
28. T. Yi, Y. Chen, L. Wang, and G. Du Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease Blood 14 2009 3101
29. L.E. Harrington, R.D. Hatton, and P.R. Mangan Interleukin- 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nat Immunol 6 2005 1123